Trial Profile
Scheme of treatment with high-dose lanreotide in acromegalic patients poorly responsive to treatment with standard doses." "Schema di trattamento con lanreotide ad alte dosi in pazienti acromegalici scarsamente responsivi al trattamento con dosi standard".
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Mar 2016
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Sponsors Ipsen SPA
- 16 Mar 2016 Status changed from recruiting to completed as per European Clinical Trials Database record.
- 27 May 2014 New trial record